Barrett's Oesophagus: What It Is, Who Gets It, and Why Monitoring Cannot Be Skipped

Barrett's oesophagus is the condition that turns chronic, untreated GERD from an unpleasant inconvenience into a serious health risk. It is a pre-cancerous change — the normal squamous lining of the lower oesophagus is replaced by a type of intestinal columnar epithelium that should not be there, triggered by years of acid exposure. Barrett's oesophagus itself does not cause symptoms beyond GERD, but it carries an elevated risk of progressing to oesophageal adenocarcinoma — a cancer with a poor prognosis when detected late and an excellent prognosis when caught at the dysplastic or early invasive stage through surveillance endoscopy.

How Barrett's Oesophagus Develops

In GERD, repeated acid contact with the squamous lining of the lower oesophagus damages the cells and triggers a healing response. In some patients — those with long-standing, severe reflux — this healing response produces a metaplastic change: the original squamous cells are replaced by columnar (glandular) cells resembling intestinal lining. This replacement tissue is more acid-resistant than squamous epithelium, which explains why some patients with Barrett's oesophagus actually notice an improvement in heartburn symptoms — the metaplastic tissue is less pain-sensitive. This symptomatic "improvement" does not mean the situation has improved clinically; it means the biology of the tissue has changed, and the risk profile has changed with it.

Who Is at Risk of Barrett's Oesophagus?

The risk factors for Barrett's oesophagus reflect the severity and duration of acid exposure to the oesophageal lining:

• Long-standing GERD (symptoms present for 5 or more years) — the primary risk factor
• Male sex — Barrett's oesophagus is approximately 3 times more common in men than women, for reasons that are not fully understood
• Age over 50 — prevalence increases with age
• Obesity — central obesity increases intra-abdominal pressure and reflux severity
• Smoking — tobacco use is an independent risk factor for Barrett's oesophagus and oesophageal adenocarcinoma
• Caucasian race — Barrett's oesophagus has been traditionally considered more common in Western populations, but Indian data increasingly shows its prevalence is rising with the Westernisation of diet and lifestyle
• Family history of Barrett's oesophagus or oesophageal cancer

An important point: some patients with Barrett's oesophagus have minimal or no GERD symptoms. The acid exposure that caused the metaplastic change may not be experienced as heartburn in every patient — particularly those who have developed the characteristic insensitivity of Barrett's mucosa to acid.

Barrett's Oesophagus and Cancer Risk: Understanding the Numbers

The annual risk of progression from Barrett's oesophagus to oesophageal adenocarcinoma is approximately 0.3–0.5% per year in patients with non-dysplastic Barrett's (no abnormal cell changes beyond the metaplasia itself). This absolute risk sounds small — but over 15–20 years of unmonitored Barrett's, it accumulates. The risk is significantly higher in patients who develop low-grade dysplasia (LGD) and substantially higher in high-grade dysplasia (HGD), where cancer may already be present focally.

The cancer that develops from Barrett's oesophagus — oesophageal adenocarcinoma — has a 5-year survival rate of under 20% when detected at advanced stages. When detected at the dysplastic or T1 stage through surveillance endoscopy, curative endoscopic treatment (radiofrequency ablation, endoscopic mucosal resection) is available, with survival rates above 80%. Surveillance endoscopy saves lives by finding dysplasia and early cancer before they become surgically incurable.

Barrett's Oesophagus Surveillance Protocol

At Solo Clinic GI, Barrett's oesophagus is managed according to international consensus guidelines:

• Non-dysplastic Barrett's oesophagus: Endoscopy with systematic biopsies (4-quadrant protocol every 2cm) every 3–5 years, with optimised PPI therapy to reduce ongoing acid exposure
• Low-grade dysplasia (LGD): Repeat endoscopy in 6 months to confirm the finding (LGD has significant inter-observer variability among pathologists). If confirmed on two biopsies, endoscopic ablation therapy (radiofrequency ablation — RFA) is considered to eliminate the dysplastic epithelium
• High-grade dysplasia (HGD): Endoscopic treatment (RFA or endoscopic mucosal resection) in eligible patients, with MDT discussion. Surgery is reserved for patients with invasive cancer or HGD not amenable to endoscopic management

Frequently Asked Questions

Can Barrett's oesophagus be reversed?

Non-dysplastic Barrett's oesophagus (without cell atypia) does not spontaneously reverse — the metaplastic change is essentially permanent once established. However, aggressive acid suppression with PPIs slows the rate of progression and may reduce dysplasia risk. Endoscopic ablation (radiofrequency ablation) can destroy Barrett's epithelium over multiple sessions, allowing re-growth of normal squamous tissue — but this is typically reserved for patients with confirmed dysplasia rather than non-dysplastic Barrett's.

I have Barrett's oesophagus but feel fine. Do I really need surveillance endoscopy?

Yes — this is precisely the point. Barrett's oesophagus produces no symptoms beyond GERD (and some patients have reduced symptoms as described above). Dysplasia and early oesophageal cancer developing within Barrett's mucosa are also asymptomatic until late. Surveillance endoscopy with biopsy is the only way to detect these changes while they are still at a treatable, curable stage. Feeling fine is not a reason to defer surveillance — it is the expected state for someone with non-dysplastic Barrett's.

Does taking PPIs prevent Barrett's oesophagus from becoming cancer?

PPIs reduce acid exposure to the Barrett's mucosa and appear to reduce the rate of progression to dysplasia in observational studies — though this has not been conclusively proven in randomised trials. The current consensus is that patients with Barrett's oesophagus should be on optimised PPI therapy (at the lowest dose that controls reflux symptoms) as part of their management. PPIs are not a substitute for surveillance endoscopy — they modify the risk environment but do not eliminate it.

Long-Standing GERD and Never Had an Endoscopy? That Needs to Change.

Barrett's oesophagus is found in approximately 10–15% of patients with longstanding GERD who undergo endoscopy. Solo Clinic GI offers AI-assisted upper GI endoscopy with systematic Barrett's biopsy protocol — the most accurate available assessment.

Book a Barrett's Assessment →    Call +91 98500 89371

Medical Disclaimer: Barrett's oesophagus management requires specialist endoscopic assessment and follow-up. This article is for informational purposes only. Consult Dr. Rajesh Tandulwadkar for a surveillance plan specific to your Barrett's extent and dysplasia status.